Cargando…

Characterization of Alzheimer’s tau biomarker discordance using plasma, CSF, and PET

BACKGROUND: We aimed to investigate the tau biomarker discrepancies of Alzheimer’s disease (AD) using plasma tau phosphorylated at threonine 181 (p-tau181), cerebrospinal fluid (CSF) p-tau181, and AV1451 positron emission tomography (PET). METHODS: In the Alzheimer’s Disease Neuroimaging Initiative,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Guo, Yu, Huang, Yu-Yuan, Shen, Xue-Ning, Chen, Shi-Dong, Hu, Hao, Wang, Zuo-Teng, Tan, Lan, Yu, Jin-Tai
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8094494/ https://www.ncbi.nlm.nih.gov/pubmed/33947453 http://dx.doi.org/10.1186/s13195-021-00834-3

Ejemplares similares

Plasma phosphorylated-tau181 as a predictive biomarker for Alzheimer’s amyloid, tau and FDG PET status
por: Shen, Xue-Ning, et al.
Publicado: (2021)

Discordant Alzheimer's neurodegenerative biomarkers and their clinical outcomes
por: Guo, Yu, et al.
Publicado: (2020)

Tau PET correlates with different Alzheimer’s disease‐related features compared to CSF and plasma p‐tau biomarkers
por: Ossenkoppele, Rik, et al.
Publicado: (2021)

Longitudinal plasma phosphorylated tau 181 tracks disease progression in Alzheimer’s disease
por: Chen, Shi-Dong, et al.
Publicado: (2021)

Staging tau pathology with tau PET in Alzheimer’s disease: a longitudinal study
por: Chen, Shi-Dong, et al.
Publicado: (2021)

Discordant amyloid-β PET and CSF biomarkers and its clinical consequences
por: de Wilde, Arno, et al.
Publicado: (2019)

Plasma tau complements CSF tau and P-tau in the diagnosis of Alzheimer's disease
por: Fossati, Silvia, et al.
Publicado: (2019)

Plasma amyloid, tau, and neurodegeneration biomarker profiles predict Alzheimer's disease pathology and clinical progression in older adults without dementia
por: Shen, Xue‐Ning, et al.
Publicado: (2020)

Characterization of Novel CSF Tau and ptau Biomarkers for Alzheimer’s Disease
por: Meredith Jr., Jere E., et al.
Publicado: (2013)

Caspase-1 variant influencing CSF tau and FDG PET levels in non-demented elders from the ADNI cohort
por: Liu, Yi, et al.
Publicado: (2022)

Is tau in the absence of amyloid on the Alzheimer’s continuum?: A study of discordant PET positivity
por: Weigand, Alexandra J, et al.
Publicado: (2019)

CSF P-tau 231 as Biomarker in Alzheimer's Disease
por: Mukherjee, Adreesh, et al.
Publicado: (2022)

Correction to: Caspase-1 variant influencing CSF tau and FDG PET levels in non-demented elders from the ADNI cohort
por: Liu, Yi, et al.
Publicado: (2022)

Plasma Protein Biomarkers for the Prediction of CSF Amyloid and Tau and [(18)F]-Flutemetamol PET Scan Result
por: Westwood, Sarah, et al.
Publicado: (2018)

Longitudinal tau and metabolic PET imaging in relation to novel CSF tau measures in Alzheimer’s disease
por: Leuzy, Antoine, et al.
Publicado: (2019)

(18)F‐AV‐1451 and CSF T‐tau and P‐tau as biomarkers in Alzheimer's disease
por: Mattsson, Niklas, et al.
Publicado: (2017)

CSF sTREM2 in delirium—relation to Alzheimer’s disease CSF biomarkers Aβ42, t-tau and p-tau
por: Henjum, Kristi, et al.
Publicado: (2018)

CSF p-tau231: A biomarker for early preclinical Alzheimer?
por: Suárez-Calvet, Marc
Publicado: (2022)

CSF MTBR-tau243 is a specific biomarker of tau tangle pathology in Alzheimer’s disease
por: Horie, Kanta, et al.
Publicado: (2023)

Agreement of amyloid PET and CSF biomarkers for Alzheimer's disease on Lumipulse
por: Alcolea, Daniel, et al.
Publicado: (2019)

Predicting amyloid PET and tau PET stages with plasma biomarkers
por: Jack, Clifford R, et al.
Publicado: (2023)

Fasting blood glucose and cerebrospinal fluid Alzheimer’s biomarkers in non-diabetic cognitively normal elders: the CABLE study
por: Ou, Ya-Nan, et al.
Publicado: (2020)

CSF tau protein and FDG PET in patients with aging-associated cognitive decline and Alzheimer’s disease
por: Hunt, Aoife, et al.
Publicado: (2006)

Dynamic changes of CSF sTREM2 in preclinical Alzheimer’s disease: the CABLE study
por: Ma, Ling-Zhi, et al.
Publicado: (2020)

The dynamics of plasma biomarkers across the Alzheimer’s continuum
por: Guo, Yu, et al.
Publicado: (2023)

CSF tau phosphorylation occupancies at T217 and T205 represent improved biomarkers of amyloid and tau pathology in Alzheimer’s disease
por: Barthélemy, Nicolas R., et al.
Publicado: (2023)

CSF metabolites associate with CSF tau and improve prediction of Alzheimer's disease status
por: Dong, Ruocheng, et al.
Publicado: (2021)

Novel CSF tau biomarkers can be used for disease staging of sporadic Alzheimer’s disease
por: Salvadó, Gemma, et al.
Publicado: (2023)

MAPT rs242557 variant is associated with hippocampus tau uptake on (18)F-AV-1451 PET in non-demented elders
por: Shen, Xue-Ning, et al.
Publicado: (2019)

Dissociation of amyloid biomarkers in PET and CSF in Alzheimer’s disease: a case report
por: Schroeter, Matthias L., et al.
Publicado: (2015)

Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease
por: Palmqvist, Sebastian, et al.
Publicado: (2015)

CSF p-Tau levels in the prediction of Alzheimer's disease
por: Kandimalla, Ramesh J. L., et al.
Publicado: (2013)

FDG-PET as an independent biomarker for Alzheimer’s biological diagnosis: a longitudinal study
por: Ou, Ya-Nan, et al.
Publicado: (2019)

β-Amyloid–Dependent and –Independent Genetic Pathways Regulating CSF Tau Biomarkers in Alzheimer Disease
por: Kumar, Atul, et al.
Publicado: (2022)

CSF GAP-43 as a biomarker of synaptic dysfunction is associated with tau pathology in Alzheimer’s disease
por: Qiang, Qiang, et al.
Publicado: (2022)

Discordant CSF/plasma HIV-1 RNA in patients with unexplained low-level viraemia
por: Nightingale, Sam, et al.
Publicado: (2016)

CSF neurogranin or tau distinguish typical and atypical Alzheimer disease
por: Wellington, Henrietta, et al.
Publicado: (2018)

PET and CSF amyloid-β status are differently predicted by patient features: information from discordant cases
por: Reimand, Juhan, et al.
Publicado: (2019)

Plasma tau in Alzheimer disease
por: Mattsson, Niklas, et al.
Publicado: (2016)

CSF/plasma HIV-1 RNA discordance even at low levels is associated with up-regulation of host inflammatory mediators in CSF()
por: Nightingale, Sam, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_rouknbv6bh239vjk700jhm47a0